Risk factor
Significant default risk
Profitability factor
Excellent dividends
About
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is of fair value on EV/EBITDA, trading at neutral
Target Price
The average target price of BION.SW is 66 and suggests 46% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell